Dimitrakopoulos, F., Nikolakopoulos, A., Kottorou, A., Kalofonou, F., Liolis, E., Frantzi, T., . . . Kalofonos, H. (2020). PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors. Cancers (Basel).
Citação norma ChicagoDimitrakopoulos, Foteinos-Ioannis, et al. "PIOS (Patras Immunotherapy Score) Score Is Associated With Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated With Anti-Program Cell Death-1 (PD-1) Inhibitors." Cancers (Basel) 2020.
Deismireacht MLADimitrakopoulos, Foteinos-Ioannis, et al. "PIOS (Patras Immunotherapy Score) Score Is Associated With Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated With Anti-Program Cell Death-1 (PD-1) Inhibitors." Cancers (Basel) 2020.